SEC Filing | Abbott Laboratories

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fiorentino Edward J

(Last)

(First)

(Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK

60064-6400

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2006

3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Senior Vice President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value	71,643	D
Common shares without par value	9,378⁽¹⁾	I	profit sharing trust

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option (right to buy)⁽²⁾	02/13/2001	02/12/2008	Common shares	2,875	34.77	D
Option (right to buy)⁽²⁾	02/12/2002	02/11/2009	Common shares	40,433	42.5	D
Option (right to buy)⁽²⁾	02/11/2003	02/10/2010	Common shares	3,065	32.61	D
Option (right to buy)⁽²⁾	03/06/2001	02/08/2006	Common shares	3,998	39.92	D
Option (right to buy)⁽²⁾	03/06/2001	02/13/2007	Common shares	5,553	39.92	D
Option (right to buy)⁽²⁾	02/09/2004	02/08/2011	Common shares	53,202	45.45	D
Option (right to buy)⁽²⁾	09/15/2001	02/13/2007	Common shares	2,831	43.99	D
Option (right to buy)⁽²⁾	09/15/2001	02/08/2006	Common shares	1,575	43.99	D
Option (right to buy)⁽²⁾	09/15/2001	02/10/2010	Common shares	13,706	43.99	D
Option (right to buy)⁽²⁾	07/09/2004	07/08/2011	Common shares	21,281	44.61	D
Option (right to buy)⁽²⁾	03/15/2002	02/10/2010	Common shares	1,420	46.55	D
Option (right to buy)⁽²⁾	03/15/2002	02/12/2008	Common shares	21,812	46.55	D
Option (right to buy)⁽²⁾	02/15/2005	02/14/2012	Common shares	69,162	53.63	D
Option (right to buy)⁽²⁾	09/20/2002	02/10/2010	Common shares	14,346	50.29	D
Option (right to buy)⁽²⁾	09/20/2002	02/12/2008	Common shares	6,709	50.29	D
Option (right to buy)⁽²⁾	02/14/2006	02/13/2013	Common shares	23,054	33.23	D
Option (right to buy)⁽²⁾	02/14/2005	02/13/2013	Common shares	1	33.23	D
Option (right to buy)⁽²⁾	12/01/2003	02/10/2010	Common shares	13,009	41.18	D
Option (right to buy)⁽²⁾	08/18/2004	02/13/2013	Common shares	20,420	41.64	D
Option (right to buy)⁽²⁾	02/20/2005	02/19/2014	Common shares	14,188	41.03	D
Option (right to buy)⁽²⁾	02/20/2006	02/19/2014	Common shares	14,187	41.03	D
Option (right to buy)⁽²⁾	02/20/2007	02/19/2014	Common shares	14,186	41.03	D
Option (right to buy)⁽²⁾	06/10/2005	02/12/2008	Common shares	5,405	43.86	D
Option (right to buy)⁽²⁾	06/10/2005	02/08/2006	Common shares	1,582	43.86	D
Option (right to buy)⁽³⁾	02/18/2006	02/17/2015	Common shares	15,467	46.34	D
Option (right to buy)⁽³⁾	02/18/2007	02/17/2015	Common shares	15,467	46.34	D
Option (right to buy)⁽³⁾	02/18/2008	02/17/2015	Common shares	15,466	46.34	D
Option (right to buy)⁽³⁾	09/09/2005	02/13/2013	Common shares	19,039	46.65	D
Option (right to buy)⁽³⁾	06/24/2006	02/13/2007	Common shares	2,653	40.74	D

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of January 3, 2006.

2. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3.

3. Employee stock options granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.

	John A. Berry, by power of attorney for Edward J. Fiorentino	01/11/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24.1

POWER OF ATTORNEY

The undersigned constitutes and appoints, LAURA J. SCHUMACHER, JOHN A. BERRY and DEBORAH K. KOENEN, and each of them individually, as the undersigned’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for the undersigned and in the undersigned’s name, place and stead, to sign any and all Securities and Exchange Commission (“SEC”) statements of beneficial ownership of securities on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite and necessary to be done under said Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Dated: January 2, 2006

	/s/ Edward J. Fiorentino
	Signature of Reporting Person

	Edward J. Fiorentino
	Senior Vice President
	Name and Title



	Abbott Laboratories
	100 Abbott Park Road
	Abbott Park, IL 60064-6400